Downloads
Title
Source name
Date

Johnson & Johnson seeks U.S. FDA approval of SPRAVATO

Phase 4 SPRAVATO® monotherapy data shows rapid improvement in depressive symptoms at ~24 hours, sustained through at least 4 weeks Monotherapy submission builds on more than a decade of research, 31 c

Johnson & Johnson
22 Jul 2024

By the numbers: Understanding dry eye disease

For National Dry Eye Awareness Month, learn about DED, particularly MGD, and how Johnson & Johnson is helping to treat this common condition.

Johnson & Johnson
18 Jul 2024

What you need to know about Johnson & Johnson’s 2024 second quarter earnings

Johnson & Johnson shared its 2024 Q2 earnings report. Get the latest on Johnson & Johnson's earnings and performance.

Johnson & Johnson
17 Jul 2024

Johnson & Johnson reports Q2 2024 results

• 2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine o

Johnson & Johnson
17 Jul 2024

Johnson & Johnson strengthens pipeline to lead in atopic dermatitis with acquisition of Yellow Jersey Therapeutics

NM26 is a Phase 2-ready, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD) The Company is leveraging a multi-pathway approach to transform treatment

Johnson & Johnson
11 Jul 2024

What to know about We All Belong: 2023 DEI Impact Review

The 2023 DEI Impact review highlights progress in meeting Johnson and Johnson's DEI goals toward creating a healthier, more equitable world.

Johnson & Johnson
09 Jul 2024

Johnson & Johnson Receives Approval from U.S. FDA and European Commission for SIRTURO

Approvals supported by Phase 3 STREAM Stage 2 study results confirming favorable treatment outcomes compared to injectable-containing regimens Approvals of SIRTURO® follow accelerated approval by U.S.

Johnson & Johnson
08 Jul 2024

Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class

First-and-only FcRn blocker to demonstrate superiority in activities of daily living (MG-ADLa) over placebo when added to standard of care over 24 weeks in antibody positive patients: anti-AChR+, anti-MuSK+, anti-LRP4+

Johnson & Johnson
08 Jul 2024

CHMP adopts positive opinion for BALVERSA

Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s most common cancers1 The CHMP’s recommendatio

Johnson & Johnson
08 Jul 2024

Innovative Medicine

Learn about pharmaceutical products for treatments including immunology, cardiovascular disease, pulmonary hypertension, infectious diseases, and oncology.

Johnson & Johnson
26 Jun 2024

Getting in front of cancer

For National Cancer Survivors Month, we spoke with Jeffrey Infante, M.D., about Johnson & Johnson's cutting-edge advances in cancer treatment that are transforming prognoses.

Johnson & Johnson
26 Jun 2024

Johnson & Johnson spotlights nipocalimab at FMF Congress 2024 – the first and only FcRn blocker to be studied in maternal fetal diseases

The Phase 3 AZALEA and Phase 3 FREESIA clinical studies are enrolling pregnant individuals who are at risk for severe HDFN and FNAIT These rare and potentially life-threatening alloantibody diseases a

Johnson & Johnson
25 Jun 2024

Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program

Co-Founded with Lions Clubs International Foundation, Sight For Kids Expands to Provide Life-Changing Eye Health · Historic High: Largest-known, school-based eye health program serves record number of

Johnson & Johnson
24 Jun 2024
We use cookies to enhance your browsing experience. By continuing to use our website you agree to our policies Read the policyAccept